Evidence Hub

Therapeutic Effect of Suzetrigine in the Management of Notalgia Paresthetica: A Case Report

Lee B, Wang W, Cha D, Lin J

Pain medicine case reports, 2026

Abstract

BACKGROUND: Notalgia paresthetica is a sensory neuropathy characterized by severe pruritus, pain, and hyperpigmented patches in the T2-T6 distribution. Despite multiple treatment options, there are no established guidelines to manage this challenging sensory neuropathy.

CASE REPORT: A 64-year-old man presented to the pain clinic with persistent notalgia paresthetica for 5 years. He was unable to tolerate oral neuropathic agents, and insurance coverage for capsaicin cream and botulinum toxin injections was denied. He was treated with suzetrigine, a novel NaV1.8 channel inhibitor, for 1 month and experienced complete resolution of symptoms.

CONCLUSIONS: The etiology of notalgia paresthetica has not been fully elucidated, but it is thought to involve irritation and aberrant firing of the thoracic spinal nerves.

UNLABELLED: This response to suzetrigine suggests that it may act as a peripheral nerve membrane stabilizer and may be a treatment option for this condition.

How strong is the evidence?

Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free